CLP Bibliography

1. Bronheim HE, Fulop G, Kunkel EJ, et al:  The Academy of Psychosomatic Medicine practice guidelines for psychiatric consultation in the general medical setting. The Academy of Psychosomatic Medicine.  Psychosomatics 1998; 39(4):S8-30. 
2. Bush KA, Fawcet J, Jacobs DG:  Clinical Correlates of Inpatient Suicide.  J Clin Psychiatry 2003; 64(1):14-19.
3. DIMatteo MR, Lepper HS, Croghan TW:  Depression is a risk factor for noncompliance with medical treatment.  Arch Intern Med 2000; 160(14):2101-2107.
4. Groves JE:  Management of the borderline patient on a medical or surgical ward: the psychiatric consultan'ts role.  Int J Psychiatry Med 1975; 6(3):337-348.
5. Groves JE:  Taking care of the hateful patient.  N Engl J Med 1978; 298(16):883-887.
6. Levenson JL (ed):  American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, 2nd Edition.  Washington DC, American Psychiatric Publishing, Inc., 2011.
7. Mohl PC, Cohen-Cole SA:  Basic readings in consultation psychiatry.  Psychosomatics 1985; 26(5):431-437.  One of the original, broad-based bibliographies, with many outstanding articles of interest. 
8. Gitlin DF, Schindler BA, Stern TA, et al:  Recommended guidelines for consultation-liaison psychiatry training in psychiatry residency programs.  A report from the Academy of Psychosomatic Medicine Task Force on Psychiatric Resident Training in Consultation-Liaison Psychiatry.  Psychosomatics 1996; 37(1):3-11.
9. Stern TA, Freudenreich O, Smith F, Fricchione G, Rosenbaum J:  MGH Handbook of General Hospital Psychiatry, 7th Edition.  Philadelphia: Elsevier, 2017.
10. Kleespies PM, Hough S, Romeo AM:  Suicide risk in people with medical and terminal illness, in Behavioral Emergencies: An Evidence-based Resource for Evaluating and Managing Risk of Suicide, Violence, and Victimization. Washington, DC, American Psychogolical Association, 2009, pp 103-121.  Good review of suicide risk associated with specific medical illnesses, some of the likely sources of increased risk, and brief summary of Oregon Assisted Suicide experience.
11. Sklansky M, Nadkarni N, Ramirez-Avila L:  Banning the Handshake From the Health Care Setting.  JAMA 2014; 311(24):2477-2478. [No abstract available.]
12. Freudenreich O, Huffman JC, Sharpe M, et al:  Updates in psychosomatic medicine: 2014. Psychosomatics 2015; 56(5):445-459. Annotations of 14 articles published in 2014 selected to be of particular relevance for PM psychiatrists. The 14 annotations (and 74 more) first appeared on the ACLP website under the Annotated Abstracts project of the ACLP Research & Evidence-Based Practice Committee.

1. Battaglia J:  Pharmacological management of acute agitation.  Drugs 2005; 65(9):1207-1222.
2. Marder SR:  A review of agitation in mental illness: treatment guidelines and current therapies.  J Clin Psychiatry 2006; 67 Suppl 10:13-21.
3. Rund DA, Ewing JD, Mitzel K, Votolato N:  The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department.  J Emerg Med 2006; 31(3):317-324.

1. Norris L:  Psychiatric issues in bariatric surgery.  Psychiatr Clin North Am 2007; 30(4):717-738. Excellent overview from a psychiatrist who regularly evaluates such patients.
2. Rydén A, Karlsson J, Sullivan M, Torgerson JS, Taft C:  Coping and distress: what happens after intervention? A 2-year follow-up from the Swedish Obese Subjects (SOS) study.  Psychosom Med 2003; 65(3):435-442.
3. Bauchowitz AU, Gonder-Frederick LA, Olbrisch ME, et al:  Psychosocial evaluation of bariatric surgery candidates: a survey of present practices.  Psychosom Med  2005; 67(5):825-832. Reviews the current status of evaluating such candidates for bariatric surgery.
4. Sjöström L, Narbro K, Sjöström CD, et al:  Effects of bariatric surgery on mortality in Swedish obese subjects.  N Engl J Med 2007; 357(8):741-752.  The most comprehensive follow-up to-date regarding the actual efficacy of such surgery.
5. Wadden TA, Sarwer DB, Womble LG, Foster GD, McGuckin BG, Schimmel A:  Psychosocial aspects of obesity and obesity surgery.  Surg Clin North Am 2001; 81(5):1001-1024.
6. Sarwer DB, Wadden TA, Fabricatore AN:  Psychosocial and behavioral aspects of bariatric surgery.  Obes Res 2005; 13(4):639-648.  Excellent review.
7. Wadden TA, Sarwer DB, Williams NN:  Behavioral assessment and characteristics of patients seeking bariatric surgery.  Obesity (Silver Spring) 2006; 14 Suppl 2:51S-52S.
8. Wadden TA, Sarwer DB:  Behavioral assessment of candidates for bariatric surgery: a patient-oriented approach.  Obesity (Silver Spring) 2006; 14 Suppl 2:53S-62S.
9. Wadden TA, Sarwer DB, Fabricatore AN, Jones L, Stack R, Williams NS:  Psychosocial and behavioral status of patients undergoing bariatric surgery: what to expect before and after surgery.  Med Clin North Am 2007; 91(3):451-469, xi-xii.

1. Raison CL, Miller AH:  Depression in cancer: new developments regarding diagnosis and treatment.  Biol Psychiatry 2003; 54(3):283-294.
2. Spiegel D, Giese-Davis J:  Depression and cancer: mechanisms and disease progression.  Biol Psychiatry 2003; 54(3):269-282.
3. Brown LF, Kroenke K:  Cancer-related fatigue and its associations with depression and anxiety: a systematic review.  Psychosomatics 2009; 50(5):440-447.

1. Barth J, Schumacher M, Herrmann-Lingen C:  Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis.  Psychosom Med 2004; 66(6):802-813.
2. Carney RM, Freedland KE:  Depression, mortality and medical morbidity in patients with coronary heart disease.  Biol Psychiatry 2003; 54(3):241-247.
3. Frasure-Smith N, Lespérance F, Talajic M:  Depression and 18-month prognosis after myocardial infarction.  Circulation 1995; 91(4):999-1005.
4. Glassman AH, O’Connor CH, Califf RM, et al:  Sertraline treatment of major depression in patients with acute MI or unstable angina.  JAMA 2002; 288(6):701-709.
5. Joynt KE, Whellan DJ, O'Connor CM:  Depression and cardiovascular disease: mechanisms of interaction.  Biol Psychiatry 2003; 54(3):248-261.
6. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al:  Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association.  Circulation 2008; 118(17):1768-1775.
7. Morita H, Wu J, Zipes DP:  The QT syndromes: long and short.  Lancet 2008; 372(9640):750-763.
8. O'Connor CM, Jiang W, Kuchibhatla M, et al:  Antidepressant use, depression, and survival in patients with heart failure.  Arch Intern Med 2008; 168(20):2232-2237.
9. Pozuelo L, Tesar G, Zhang J, Penn M, Franco K, Jiang W:  Depression and heart disease: what do we know, and where are we headed? Cleve Clin J Med 2009; 76(1):59-70.
10. Taylor D:  Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety.  Acta Psychiatr Scand 2008; 118(6):434-432.
11. Lespérance F, Frasure-Smith N, Talajic M, Bourassa MG: Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction.  Circulation 2002; 105(9):1049-1053.
12. QT Drug Lists: Drugs that Prolong the QT Interval and/or Induce Torsades de Pointes Ventricular Arrhythmia. Arizona Center for Education & Research on Therapeutics (CERT).
13. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM:  Assessing QT interval prolongation and its associated risks with antipsychotics.  CNS Drugs 2011; 25(6):473-490
14. Hondeghem LM:  Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.  J Cardiovasc Electrophysiol 2006; 17(3):337-340.
15. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC: QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54(1):1-13.
16. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC: Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75(5):e441-449.
17. Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896):951-962.
18. Kim JM, Stewart R, Lee YS, et al: Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA 2018; 320(4):350-357.
19. Smolderen KG, Buchanan DM, Gosch K, et al: Depression treatment and 1-year mortality after acute myocardial infarction: insights from the TRIUMPH registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status). Circulation 2017; 135(18):1681-1689.
20. Gathright EC, Goldstein CM, Josephson RA, Hughes JW: Depression increases the risk of mortality in patients with heart failure: a meta-analysis. J Psychosom Res. 2017; 94:82-89.

Additional resources for collaborative care/integated medicine articles are included in the Collaborative Care section of the AIMS Center website and the Institute for Healthcare Improvement's "Playbook" site.

1. Huffman JC, Niazi SK, Rundell JR, Sharpe M, Katon W:  Essential Articles on Collaborative Care Models for the Treatment of Psychiatric Disorders in Medical Settings: A Publication by the Academy of Psychosomatic Medicine Research and Evidence-Based Practice Committee. Psychosomatics 2014; 55(2):109-122.
   [Note: this is one of several monographs developed by ACLP and the European Association of Psychosomatic Medicine (EAPM). See more monographs here.]
2. Ballenger JC, Davidson JR, Lecrubier Y, et al:  Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety.  J Clin Psychiatry 2001; 62 Suppl 11:53-58.
3. Depression in primary care: detection, diagnosis, and treatment.  Agency for Health Care Policy and Research [now the Agency for Healthcare Research & Quality].  Clin Pract Guide Quick Ref Guide Clin 1993; Apr;(5):1-20.  Meta-analysis of depression in primary care and guidelines for the PCP to treat uncomplicated depression.
4. Kessler LG, Burns BJ, Shapiro S, et al:  Psychiatric diagnoses of medical service users: evidence from the Epidemiologic Catchment Area Program.  Am J Public Health 1987; 77(1):18-24. Seminal article about the prevalence of psychiatric disorders in the community.
5. Regier DA, Narrow WE, Rae DS, et al:  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.  Arch Gen Psychiatry 1993; 50(2):85-94. ECA showing psychiatric disorders use of medical services.
6. Simon GE, Katon WJ, VonKorff M, et al:  Cost-effectiveness of a collaborative care program for primary care patients with persistent depression.  Am J Psychiatry 2001; 158(10):1638-1644. Model of care improving depression treatment in PC using psychiatric service.
7. Trivedi MH, Rush AJ, Wisniewski SR, et al:  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.  Am J Psychiatry 2006; 163(1):28-40.  Seminal article about medication response evaluation of patients with comorbid medical conditions.
8. Unützer J, Rubenstein L, Katon WJ, et al:  Two-year effects of quality improvement programs on medication management for depression.  Arch Gen Psychiatry 2001; 58(10):935-942.
9. Wells KB, Stewart A, Hays RD, et al:  The functioning and well-being of depressed patients. Results from the Medical Outcomes Study.  JAMA 1989; 262(7):914-919.  Comparison of health-related quality of life for depressed patients in primary care with six other medical conditions.
10. Wells KB, Burnam MA, Rogers W, Hays R, Camp P:  The course of depression in adult outpatients. Results from the Medical Outcomes Study.  Arch Gen Psychiatry 1992; 49(10):788-794.  MOS focus of depression course over time.
11. Wittchen HU:  Generalized anxiety disorder: prevalence, burden, and cost to society.  Depress Anxiety 2002; 16(4):162-171.
12. Zinbarg RE, Barlow DH, Liebowitz M, et al:  The DSM-IV Field Trial for Mixed Anxiety-Depression.  Am J Psychiatry 1994; 151(8):1153-1162.  Field-trial determining symptoms that define the disorder, and development of criteria for DSM-IV to be used for research for Mixed-Anxiety Depression.
13. Katon WJ, Lin EH, Von Korff M, et al: Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010; 363(27):2611-2620.
14. Viron MJ, Stern TA: The impact of serious mental illness on health and healthcare. Psychosomatics 2010; 51(6):458-465.
15. Wiles N, Thomas L, Abel A, et al: Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013; 381:375-84.
16. Frankel S, Bourgeois JA (eds): Integrated Care for Complex Patients: A Narrative Medicine Approach. Springer International Publishing, 2018.

1. Alvarez-Jimenez M, González-Blanch C, Crespo-Facorro B, et al:  Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal.  CNS Drugs 2008; 22(7):547-562.
2. Baptista T, ElFakih Y, Uzcátegui E, et al:  Pharmacological management of atypical antipsychotic-induced weight gain.  CNS Drugs 2008; 22(6):477-495.
3. Vieweg WV, Levy JR, Fredrickson SK, et al:  Psychotropic drug considerations in depressed patients with metabolic disturbances.  Am J Med 2008; 121(8):647-655.
4. Yager J, Andersen AE:  Clinical practice. Anorexia nervosa.  N Engl J Med 2005; 353(14):1481-1488.

1. Hall RCW:  Psychiatric effects of thyroid hormone disturbance.  Psychosomatics 1983; 24(1):7-11, 15-18.
2. Heinrich TW, Grahm G:  Hypothyroidism presenting as psychosis: myxedema madness revisited.  Prim Care Companion J Clin Psychiatry 2003; 5(6):260–266.
3. Musselman DL, Betan E, Larsen H, Phillips LS:  Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment.  Biol Psychiatry 2003; 54(3):317-329.
4. Westphal SA:  Unusual presentations of hypothyroidism.  Am J Med Sci 1997; 314(5):333-337.
5. Katon W, Russo J, Lin EH, et al:  Depression and diabetes: factors associated with major depression at five-year follow-up.  Psychosomatics 2009; 50(6):570-579.

1. Arnold LM, Bradley LA, Clauw DJ, Glass JM, Goldenberg DL:  Evaluating and diagnosing fibromyalgia and comorbid psychiatric disorders.  J Clin Psychiatry 2008; 69(10):e28.  This is best reviewed via Internet and is a good initial review of the subject.
2. Goldenberg DL:  Multidisciplinary modalities in the treatment of fibromyalgia.  J Clin Psychiatry 2008; 69 Suppl 2:30-34.  Good review of various treatments in this disorder
3. Mease P, Arnold LM, Bennett R, et al:  Fibromyalgia syndrome.  J Rheumatol 2007; 34(6):1415-1425.
4. Clauw DJ:  Assessing and diagnosing fibromyalgia in the clinical setting.  J Clin Psychiatry 2008; 69(11):e33.
5. Hauser W, Bernardy K, Uceyler N, Sommer C:  Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis.  JAMA 2009; 301(2):198-209. Concludes that antidepressants have a role in management.
6. DeSantana JM, Sluka KA:  Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain.  Curr Pain Headache Rep 2008; 12(5):338-343.  Clear and concise summary of the concept of central processing pathology as a factor in explaining fibromyalgia.
7. Paiva ES, da Costa ED, Scheinberg M:  Fibromyalgia: an update and immunological aspects.  Curr Pain Headache Rep 2008;12(5):321-326.  Excellent review of the current status of this approach to finding a pathologic explanation for fibromyalgia.

1. Creed F, Fernandes L, Guthrie E, et al:  The cost effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.  Gastroenterology 2003; 124(2):303-317.
2. Drossman DA, Tally NJ, Leserman J, Olden KW, Barreiro MA:  Sexual and physical abuse and gastrointestinal illness. Review and recommendations.  Ann Intern Med 1995; 123(10):782-794.
3. Drossman DA, Toner BB, Whitehead WE, et al:  Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.  Gastroenterology 2003; 125(1):19-31.
4. Eaton WW, Mortensen PB:  Coeliac disease and schizophrenia: population based case control study with linkage of Danish national registers.  BMJ 2004; 328:438-439.
5. Whitehead WE, Palsson O, Jones KR:  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122(4):1140-1156.

1. 1. ACLP Research and Clinical Practice Committees: HIV Psychiatry Bibliography  [Note: This is one of several monographs developed by the ACLP. See more monographs here.]
   2. APA practice guidelines for the treatment of patients with HIV/AIDS.  Am J Psychiatry 2000; 157(11 Suppl):1-62.
   3. Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM:  Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease.  Biol Psychiatry 2003; 54(3):307-316.
   4. HIV Clinical Guidelines, New York State Department of Health AIDS Institute, 2009.  Outstanding, up-to-date resources on HIV treatment.

1. Leserman J:  HIV disease progression: depression, stress, and possible mechanisms.  Biol Psychiatry 2003; 54(3):295-306.
2. Vergara-Rodriguez, Watts:  Use of psychotropic medications in the HIV-positive patient: Part I. Psychopharm Review 2008; 43:59-65;  Part II. Psychopharm Review 2008; 43:75-81. [Articles not available online.]
3. Wynn GH, Zapor MJ, Smith BH, et al:  Antiretrovirals, part 1: overview, history, and focus on protease inhibitors.  Psychosomatics 2004; 45(3):262-270.
4. Breitbart W, Rosenfeld B, Gibson C, et al: Impact of treatment for depression on desire for hastened death in patients with advanced AIDS. Psychosomatics 2010; 51(2):98-105.
5. Davis HF, Skolasky RL Jr, Selnes OA, Burgess DM, McArthur JC: Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002; 12(1):29-31, 38.
6. Greene M, Justice, AC, Lampiris, HW, Valcour, V: Management of human immunodeficiency virus infection in advanced age. JAMA 2013; 309(13):1397-405.
7. Foisy M, Tseng A: Predicted Interactions between Psychotropics and Antiretrovirals. Toronto General Hospital, September 2014.

1. Yale Medical School Graduation Address, May 2010, by Donald M. Berwick, MD, MPP [PDF]. This is a must-read medical school graduation speech that bears greatly on the approach to bioethics in the general hospital.
2. Appelbaum PS, Grisso T:  Assessing patient’s capacities to consent to treatment.  N Engl J Med 1988; 319(25);1635-1638.
3. Garrick TR, Weinstock R:  Liability of psychiatric consultants.  Psychosomatics 1994; 35(5):474-484.
4. Sreenivasan S, Eth S, Kirkish P, Garrick T:  A practical method for the evaluation of symptom exaggeration in minor head trauma among civil litigants.  J Am Acad Psychiatry Law 2003; 31(2):220-231.
5. Tharyan P:  Evidence-based medicine: can the evidence be trusted?  Indian J Med Ethics 2011; 8(4):201-207.
6. Byatt N, Pinals D, Arikan R: Involuntary hospitalization of medical patients who lack decisional capacity: an unresolved issue.  Psychosomatics 2006; 47(5):443-448.
7. Olbrisch ME: Ethical issues in psychological evaluation of patients for organ transplant surgery [APA PsycNet link]. Rehabil Psychol 1996; 41(1):53-71.

1. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL:  Combat Duty in Iraq and Afghanistan: Mental Health Problems and Barriers to Care.  N Engl J Med 2004; 351(1):13-22.
2. Hankin CS, Spiro A, Miller DR, Kazis L:  Mental disorders and mental health treatment among U.S. Department of Veterans Affairs outpatients: the Veterans Health Study.  Am J Psychiatry 1999; 156(12):1924-1930.
3. Kulka RA, Schlenger WE, Fairbank JA, Hough RL:  Trauma and the Vietnam War Generation.  New York, Brunner/Mazel [now Brunner-Routledge], 1990.
4. Rosenheck R, Fontana A:  Do Vietnam-era veterans who suffer from posttraumatic stress disorder avoid VA mental health services? Military Medicine 1995; 160(3):136-142.
5. Samson AY, Bensen S, Beck A, Price D, Nimmer C:  Posttraumatic stress disorder in primary care.  J Fam Pract 1999; 48(3):222-227.
6. Wolfe J, Brown PJ, Bucsela ML:  Symptom Responses of Female Vietnam Veterans of Operation Desert Storm.  Am J Psychiatry 1992; 149(5):676-679.

1. ACLP Guidelines & Evidence-Based Medicine Subcommittee and the European Association of Psychosomatic Medicine (EAPM):  Traumatic Stress Disorders in Medically Ill Patients: An Evidence-Based Mediciine Monograph for Psychosomatic Medicine Practice [PDF].  December 2012.  [Note: This is one of several monographs developed in partnership with the EAPM (formerly the EACLPP). See more monographs here.]
2. Abouesh A, Stone C, Hobbs WR:  Antimicrobial-induced mania (antibiomania): a review of spontaneous reports.  J Clin Psychopharmacol 2002; 22(1):71-81.
3. González-Arriaza HI, Bostwick JM:  Acute porphyrias: a case report and review.  Am J Psychiatry 2003; 160(3):450-459.
4. Hanly JG:  Neuropsychiatric lupus.  Rheum Dis Clin North Am 2005; 31(2):273-298.
5. Krauthammer C, Klerman GL:  Secondary mania: manic symptoms associated with antecedent physical illness or drugs.  Arch Gen Psychiatry 1978; 35(11):1333-1339.
6. Menon GJ, Rahman I, Menon SJ, Dutton GN:  Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome.  Surv Ophthalmol 2003; 48(1):58-72.
7. Freudenmann RW, Lepping P:  Delusional infestation.  Clin Microbiol Rev 2009; 22(4):690-732.
8. Mattila AK, Saarni SI, Salminen JK, Huhtala H, Sintonen H, Joukamaa M:  Alexithymia and health-related quality of life in a general population.  Psychosomatics 2009; 50(1):59-68.

1. Cummings JL:  Fronto-subcortical circuits and human behavior.  Arch Neurol 1993; 50(8):873-880.
2. Chapter 6, "Limbic Music – The Band Plays On," from MGH Handbook of General Hospital Psychiatry.
3. Mega MS, Cummings JL:  Frontal-subcortical circuits and neuropsychiatric disorders.  J Neuropsychiatry Clin Neurosci 1994; 6(4):358-370.
4. Neylan TC:  Frontal  lobe function: Mr. Phineas Gage’s famous injury.  J Neuropsychiry Clin Neurosci 1999; 11(2):280-283.
5. Tekin S, Cummings JL:  Fronto-subcortical neuronal circuits and clinical neuropsychiatry: an update.  J Psychosom Res 2002; 53(2):647-654.

1. American Psychiatric Association Practice Guideline for Altzheimer's Disease and Other Dementias (2007).
2. Cummings JL:  Alzheimer’s disease.  N Engl J Med 2004; 351(1):56-67.
3. Thompson S, Herrmann N, Rapoport MJ, Lanctôt KL:  Efficacy and safety of antidepressants for treatment of depression in Alzheimer’s disease: a metaanalysis.  Can J Psychiatry 2007; 52(4):248-255.
4. McDonald WM, Richards IH, DeLong MR:  Prevalence, etiology, and treatment of depression in Parkinson's disease.  Biol Psychiatry 2003; 54(3):363-375.
5. McKeith IG, Dickson DW, Lowe J, et al:  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.  Neurology 2005; 65(12):1863-1872.
6. Weintraub D, Hurtig HI:  Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.  Am J Psychiatry 2007; 164(10):1491-1498.
7. Green RC, Schneider LS, Amato DA, et al:  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009; 302(23):2557-2264.
8. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.  J Psychiatr Res 1975; 12(3):189-198.
9. Fricchione G, Bush G, Fozdar M, et al:  Recognition and treatment of the catatonic syndrome.  J Intensive Care Med 1997; 12(3):135-147.
10. Fricchione G, Mann SC, Caroff SN:  Catatonia, lethal catatonia, and neuroleptic malignant syndrome.  Psychiatric Ann 2000; 30:347-355.  [Not available online.]
11. Kertesz A, Blair M, McMonagle P, Munoz DG:  The diagnosis and course of frontotemporal dementia.  Alzheimer Dis Assoc Disord 2007; 21(2):155-163.
12. Mendez MF, Lauterbach EC, Sampson SM; ANPA Committee on Research:  An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA committee on research.  J Neuropsychiatry Clin Neurosci 2008; 20(2):130-149.
13. Rosenblatt A, Leroi I:  Neuropsychiatry of Huntington's disease and other basal ganglia disorders.  Psychosomatics 2000; 41(1):24-30.
14. Maldonado JR, Wysong A, van der Starre PJ, Block T, Miller C, Reitz BA:  Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery.  Psychosomatics 2009; 50(3):206-217.
15. Schneider LS, Tariot PN, Dagerman KS, et al:  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.  NEJM 2006; 355(15):1525-1538.
16. Albert MS, DeKosky ST, Dickson D, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3):270-279.

Delirium

1. ACLP Guidelines & Evidence-Based Medicine Subcommittee and the European Association for Consultation-Liaison Psychiatry & Psychosomataics (EACLPP):  Delirium: An Evidence-Based Medicine Monograph for Psychosomatic Medicine Practice.  January 2012.  [Note: This is one of several monographs developed in partnership with the EACLPP (now the EAPM). See more monographs here.]
2. Breitbart W, Gibson C, Tremblay A:  The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses.  Psychosomatics 2002; 43(3):183-194.
3. Breitbart W, Alici Y:  Agitation and delirium at the end of life: "We couldn't manage him".  JAMA 2008; 300(24):2898-2910.
4. Breitbart W, Marotta R, Platt MM, et al:  A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.  Am J Psychiatry 1996; 153(2):231-237.
5. Fricchione GL, Nejad SH, Esses JA, et al:  Postoperative Delirium.  Am J Psychiatry 2008; 165(7):803-812.
6. Inouye SK:  Delirium in older persons.  N Engl J Med 2006; 354(11):1157-1165.
7. Inouye SK:  The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients.  Am J Med 1994; 97(3):278-288.
8. Inouye SK, Rushing JT, Foreman MD, Palmer RM, Pompei P:  Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study.  J Gen Intern Med 1998;13(4):234-242.
9. Jacobson S, Jerrier S:  EEG in delirium.  Semin Clin Neuropsychiatry 2000; 5(2):86-92.
10. Mayo-Smith MF, Beecher LH, Fischer TL, et al:  Management of alcohol withdrawal delirium. An evidence-based practice guideline.  Arch Intern Med 2004;164(13):1405-1412.
11. Menza MA, Murray GB, Holmes VF, Rafuls WA:  Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines.  Heart Lung 1988; 17(3):238-241.
12. Michaud L, Büla C, Berney A, et al; Delirium Guidelines Development Group.  Delirium: guidelines for general hospitals.  J Psychosom Res 2007; 62(3):371-83.
13. Milbrandt EB, Deppen S, Harrison PL, et al:  Costs associated with delirium in mechanically ventilated patients.  Crit Care Med 2004; 32(4):955-962.
14. American Psychiatric Association Practice Guideline for Delirium (1999).  Guideline Watch (2004).
15. Trepacz PT:  Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine.  Semin Clin Neuropsychiatry 2000; 5(2):132-148.
16. Larsen KA, Kelly SE, Stern TA, et al:  Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial. Psychosomatics 2010; 51(5):409-418. 
17. Martins S, Fernandes L:  Delirium in elderly people: a review.  Front Neurol 2012; 3:101.
18. Gross AF, Stern TA:  Neuropsychiatric conditions associated with anesthesia exposure. Psychosomatics 2014; 55(1):21-28.

1. Wells AJ, Sommi RW, Crismon ML:  Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review.  Drug Intell Clin Pharm 1988; 22(6):475-480.
2. Levenson JL:  Neuroleptic Malignant Syndrome.  Am J Psychiatry 1985; 142(10):1137-1145.

1. Campbell LC, Clauw DJ, Keefe FJ:  Persistent pain and depression: a biopsychosocial perspective.  Biol Psychiatry 2003; 54(3):399-409.
2. Chou R, Fanciullo GJ, Fine PG, et al:  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.  J Pain 2009; 10(2):113-130.
3. Pain: Clinical Updates.  International Association for the Study of Pain (IASP).  Excellent series of updates on pain in various psychiatric disorders; topics such as opoid hyperalgesia, and medical situations such as cancer, including treatment guidelines.

1. DeMaso DR, Martini DR, Cahen LA: Practice parameter for the psychiatric assessment and management of physically ill children and adolescents.  J Am Acad Child Adolesc Psychiatry 2009; 48(2):213-233.
2. Turkel S, Pao M:  Late consequences of chronic pediatric illness.  Psychiatr Clin North Am 2007; 30(4):819-35.
3. Pao M, Ballard ED, Raza H, Rosenstein DL:  Pediatric psychosomatic medicine: an annotated bibliography.  Psychosomatics 2007; 48(3):195-204.

1. Bronheim HE, Fulop G, Kunkel EJ, et al:  The Academy of Psychosomatic Medicine practice guidelines for psychiatric consultation in the general medical setting. The Academy of Psychosomatic Medicine.  Psychosomatics 1998; 39(4):S8-30. 
2. Cytochrome P450 Drug Interaction Table.  Indiana University School of Medicine, 2009.
3. Massand PS, Tesar GE:  Use of stimulants in the medically ill.  Psychiatr Clin North Am 1996; 19(3):515-547.
4. Spina E, Santoro V, D'Arrigo C:  Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.  Clin Ther 2008; 30(7):1206-1227.
5. Glassman AH, Bigger JT Jr:  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.  Am J Psychiatry 2001; 158(11):1774-1782.
6. Mitkov MV, Trowbridge RM, Lockshin BN, Caplan JP:  Dermatologic side effects of psychotropic medications. Psychosomatics 2014; 55(1):1-20.

1. Brenes GA:  Anxiety and chronic obstructive pulmonary disease: prevalence, impact and treatment.  Psychosom Med 2003; 65(6):963-970.

1. Cohen LM, Tessier EG, Germain MJ, Levy NB:  Update on psychotropic medication use in renal disease.  Psychosomatics 2004; 45(1):34-48.
2. Cohen LM, Germain MJ, Poppel DM:  Practical considerations in dialysis withdrawal: “to have that option is a blessing".  JAMA 2003; 289(16):2113-2119.
3. Gabardi S, Abramson S:  Drug dosing in chronic kidney disease.  Med Clin North Am 2005; 89(3):649-687.
4. Kimmel PL:  Depression in patients with chronic renal disease: what we know and what we need to know.  J Psychosom Res 2002; 53(4):951-956.
5. Kimmel PL, Cukor D, Cohen SD, Peterson RA:  Depression in end-stage renal disease patients: a critical review.  Adv Chronic Kidney Dis 2007; 14(4):328-334.

1. Bear DM, Fedio P:  Quantitative analysis of interictal behavior in temporal lobe epilepsy.  Arch Neurol 1977; 34(8):454-467.
2. Bowman ES:  Nonepileptic seizures: psychiatric framework, treatment, and outcome.  Neurology 1999; 53(5 suppl 2):S84-S88.
3. Bowman ES:  Pseudoseizures.  Psychiatr Clin North Am 1998; 21(3):649-657.
4. Kanner AM:  Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment.  Biol Psychiatry 2003; 54(3):388-398.
5. Krishnamoorthy ES, Trimble MR:  Forced normalization: clinical and therapeutic relevance.  Epilepsia 1999; 40 Suppl 10:S57-564.
6. Krumholz A, Hopp J:  Psychogenic (nonepiletic) seizures.  Semin Neurol 2006; 26(3):341-350.
7. Lancman M.  Psychosis and peri-ictal confusional states.  Neurology 1999; 53(5 Suppl 2):S33-S38.
8. Wilkus RJ, Thompson PM, Vossler DG:  Bizarre ictal automatisms: frontal lobe epileptic or psychogenic seizures.  J Epilepsy 1990; 3:207-213.  [Not available online.]
9. Wolf P:  Acute behavioral symptomatology at disappearance of epileptiform EEG abnormality. Paradoxical or "forced" normalization.  Adv Neurol 1991; 55:127-142.

1. Boyer EW, Shannon M: The serotonin syndrome.  N Engl J Med 2005; 352(11):1112-1120.
2. Mason PJ, Morris VA, Balcezak TJ:  Serotonin syndrome: presentation of 2 cases and review of the literature.  Medicine (Baltimore) 2000; 79 (4):201-209.

1. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP:  Depression, sleep physiology, and antidepressant drugs.  Depress Anxiety 2001;14(1):19-28.
2. Wise MS:  Narcolepsy and other disorders of excessive sleepiness.  Med Clin North Am 2004; 88(3):597-610.

1. Ford CV:  Somatization and fashionable diagnoses: illness as a way of life.  Scand J Work Environ Health 1997; 23 Suppl 3:7-16.
2. Creed F, Guthrie E:  Techniques for interviewing the somatising patient.  Br J Psychiatry 1993; 162:467-471.
3. Katon W, Sullivan M, Walker E:  Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits.  Ann Int Med 2001; 134 (9 Pt 2):917-925.
4. Kathol RG:  Reassurance therapy: what to say to symptomatic patients with benign or non-existent medical disease.  Int J Psychiatry Med 1997; 27(2):173-180.
5. Murphy GE:  The clinical management of hysteria.  JAMA 1982; 247(18):2559-2564.
6. Stone J, Carson A, Sharpe M:  Functional symptoms and signs in neurology: assessment and diagnosis.  J Neurol Neurosurg Psychiatry 2005; 76 Suppl 1:i2-12.
7. Stonnington CM, Barry JJ, Fisher RS:  Conversion disorder.  Am J Psychiatry 2006; 163(9):1510-1517.
8. Shorter E:  The borderland between neurology and history.  Conversion reactions.  Neurol Clin 1995; 13(2) 229-239.
9. Van Houdenhove B, Luyten P:  Customizing treatment of chronic fatigue syndrome and fibromyalgia: the role of perpetuating factors.  Psychosomatics 2008; 49(6):470-477.

Factitious Disorder, Malingering

1. Asher R: Munchausen's syndrome.  Lancet 1951; 257(6650):339-341.  [No abstract available; purchase or subscription required to view full article.]
2. Eastwood S, Bisson JI:  Management of factitious disorders: a systematic review.  Psychother Psychosom 2008; 77(4):209-218.
3. Feldman MD:  Factitious Munchausen's Syndrome—a confession.  N Engl J Med 1992; 327(6):438-439.  [No abstract available.]
4. Greer S, Chambliss L, Mackler L, Huber T:  Clinical inquiries. What physical exam techniques are useful to detect malingering? J Fam Pract 2005; 54:719-722.
5. Gurwith M, Langston C:  Factitious Munchausen's syndrome.  N Engl J Med 1980; 302(26):1483-1484.  [No abstract available.]
6. Krahn LE, Li H, O'Connor MK:  Patients who strive to be ill: factitious disorder with physical symptoms.  Am J Psychiatry 2003; 160(6):1163-1168.
7. McDermott BE, Feldman MD:  Malingering in the medical setting.  Psychiatr Clin North Am 2007; 30(4):645-662.
8. Wise MG, Ford CV:  Factitious disorders.  Prim Care 1999; 26(2):315-326.

1. Hermann N, Mamdani M, Lanctôt KL:  Atypical antipsychotics in risk of cerebrovascular accidents.  Am J Psychiatry 2004; 161(6):1113-1115.
2. Jorge RE, Robinson RG, Arndt S, Starkstein S:  Mortality and poststroke depression: a placebo-controlled trial of antidepressants.  Am J Psychiatry 2003; 160(10):1823-1829.
3. Robinson RG:  The Clinical Neuropsychiatry of Stroke (2nd Ed).  Cambridge University Press, 2012.
4. Tekin S, Cummings JL:  Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update.  J Psychosomatic Research 2002; 53(2):647-654

1. Substance Abuse Treatment Evidence-Based Practices [EBP Web Guide].  US Department of Health & Human Services, Substance Abuse & Mental Health Services Administration (SAMHSA).
2. Isenberg-Grzeda E, Kutner HE, Nicolson SE:  Wernicke-Korsakoff-syndrome: under-recognized and under-treated.  Psychosomatics 2012; 53(6):507-501.

Another resource for transplantation articles is the American Journal of Transplantion's "Virtual Issues" collection of Living Liver and Kidney Donation articles. The virtual issues are updated regularly by the editor.

1. Beresford TP, Lucey MR. Towards standardizing the alcoholism evaluation of potential liver transplant recipients. Alcohol and Alcoholism. 2017;53(2):135-144. doi:10.1093/alcalc/agx104
2. Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients. Clinical Pharmacokinetics. 2004;43(6):361-394. doi:10.2165/00003088-200443060-00002
3. Davydow DS, Lease ED, Reyes JD. Posttraumatic stress disorder in organ transplant recipients: A systematic review. General Hospital Psychiatry. 2015;37(5):387-398. doi:10.1016/j.genhosppsych.2015.05.005
4. Dew MA, DiMartini AF, Dobbels F, Grady KL et al. The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates and candidates for long-term mechanical circulatory support. J Heart Lung Transplant. 2018 Jul;37(7):803-823. doi: 10.1016/j.healun.2018.03.005.
5. Dew MA, Butt Z, Humar A, DiMartini AF. Long-Term medical and psychosocial outcomes in Living liver donors. American Journal of Transplantation. 2016;17(4):880-892. doi:10.1111/ajt.14111
6. Dew MA, Butt Z, Liu Q, et al. Prevalence and predictors of patient-reported long-term mental and physical health after donation in the adult-to-adult living-donor liver Transplantation cohort study. Transplantation. 2018;102(1):105-118. doi:10.1097/tp.0000000000001942
7. Dew MA, DiMartini AF, De Vito Dabbs A, et al. Rates and risk factors for nonadherence to the Medical regimen after adult solid organ transplantation. Transplantation. 2007;83(7):858-873. doi:10.1097/01.tp.0000258599.65257.a6
8. Dew MA, DiMartini AF, DeVito Dabbs AJ, et al. Onset and risk factors for anxiety and depression during the first 2 years after lung transplantation. General Hospital Psychiatry. 2012;34(2):127-138. doi:10.1016/j.genhosppsych.2011.11.009
9. Dew MA, DiMartini AF, Dobbels F, et al. The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates and candidates for long-term mechanical circulatory support. The Journal of Heart and Lung Transplantation. 2018;37(7):803-823. doi:10.1016/j.healun.2018.03.005
10. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transplantation. 2008;14(2):159-172. doi:10.1002/lt.21278
11. Dew MA, Jacobs CL, Jowsey SG, Hanto R, Miller C, Delmonico FL. Guidelines for the psychosocial evaluation of living unrelated kidney donors in the United States. American Journal of Transplantation. 2007;7(5):1047-1054. doi:10.1111/j.1600-6143.2007.01751.x
12. Dew MA, Kormos RL, DiMartini AF, et al. Prevalence and risk of depression and anxiety-related disorders during the first three years after heart transplantation. Psychosomatics. 2001;42(4):300-313. doi:10.1176/appi.psy.42.4.300
13. Dew MA, Rosenberger EM, Myaskovsky L, et al. Depression and anxiety as risk factors for morbidity and mortality after organ transplantation. Transplantation. 2015;100(5):988-1003. doi:10.1097/tp.0000000000000901
14. Dew MA, Switzer GE, Goycoolea JM, et al. Does transplantation produce quality of life benefits? Transplantation. 1997;64(9):1261-1273. doi:10.1097/00007890-199711150-00006
15. DiMartini A, Dew MA, Day N, et al. Trajectories of alcohol consumption following liver transplantation. American Journal of Transplantation. 2010;10(10):2305-2312. doi:10.1111/j.1600-6143.2010.03232.x
16. DiMartini AF, Dew MA. Monitoring alcohol use on the liver transplant wait list: Therapeutic and practical issues. Liver Transplantation. 2012;18(11):1267-1269. doi:10.1002/lt.23529
17. Faeder S, Moschenross D, Rosenberger E, Dew MA, DiMartini A. Psychiatric aspects of organ transplantation and donation. Current Opinion in Psychiatry. 2015;28(5):357-364. doi:10.1097/yco.0000000000000185
18. Fireman M, DiMartini AF, Armstrong SC, Cozza KL. Immunosuppressants. Psychosomatics. 2004;45(4):354-360. doi:10.1176/appi.psy.45.4.354
19. Krahn LE, DiMartini A. Psychiatric and psychosocial aspects of liver transplantation. Liver Transplantation. 2005;11(10):1157-1168. doi:10.1002/lt.20578
20. LaPointe Rudow D, Warburton KM. Selection and postoperative care of the living donor. Medical Clinics of North America. 2016;100(3):599-611. doi:10.1016/j.mcna.2016.01.009
21. Maldonado JR, Sher Y, Lolak S, et al. The Stanford Integrated Psychosocial Assessment for Transplantation. Psychosomatic Medicine. 2015;77(9):1018-1030. doi:10.1097/psy.0000000000000241
22. Myaskovsky L, Jesse MT, Kuntz K, et al. Report from the American Society of Transplantation psychosocial community of practice adherence task force: Real-world options for promoting adherence in adult recipients. Clinical Transplantation. 2018;32(9). doi:10.1111/ctr.13353
23. Olbrisch M, Benedict S, Haller D, Levenson J. Psychosocial assessment of living organ donors: Clinical and ethical considerations. Progress in Transplantation. 2001;11(1):40-49. doi:10.7182/prtr.11.1.e27186258226k604
24. Olbrisch ME, Benedict SM, Ashe K, Levenson JL. Psychological assessment and care of organ transplant patients. Journal of Consulting and Clinical Psychology. 2002;70(3):771-783. doi:10.1037/0022-006x.70.3.771
25. Rodrigue JR, Hanto DW, Curry MP. The alcohol relapse risk assessment: A scoring system to predict the risk of relapse to any alcohol use after liver transplant. Progress in Transplantation. 2013;23(4):310-318. doi:10.7182/pit2013604
26. Rodrigue JR, Pavlakis M, Danovitch GM, et al. Evaluating living kidney donors: Relationship types, psychosocial criteria, and consent processes at us transplant programs. American Journal of Transplantation. 2007;7(10):2326-2332. doi:10.1111/j.1600-6143.2007.01921.x
27. Sher Y, Zimbrean P. Psychiatric aspects of organ transplantation in critical care. Critical Care Clinics. 2017;33(3):659-679. doi:10.1016/j.ccc.2017.03.009
28. Stilley C, DiMartini A, de Vera M, et al. Individual and environmental correlates and predictors of early adherence and outcomes after liver transplantation. Progress in Transplantation. 2010;20(1):58-67. doi:10.7182/prtr.20.1.c903845857104k83

1. Hoge CW, Goldberg HM, Castro CA:  Care of war veterans with mild traumatic brain injury—flawed perspectives.  N Engl J Med 2009; 360(16):1588-1591.
2. Hoofien D, Gilboa A, Vakil E, Donovick PJ:  Traumatic brain injury (TBI) 10-20 years later: a comprehensive outcome study of psychiatric symptomatology, cognitive abilities and psychosocial functioning.  Brain Inj 2001; 15(3):189-209.
3. Rao V, Lyketsos CG:  Psychiatric aspects of traumatic brain injury.  Psychiatr Clin North Am 2002; 25(1):43-69.

1. Barnes D (ed):  Women's Reproductive Mental Health Across the Lifespan. New York, Springer, 2014.
2. Brizendine L:  The Female Brain. New York, Broadway Books, 2006.
3. World Health Organization:  Mental health aspects of women’s reproductive health: A global review of the literature. Geneva, Switzerland, WHO Press, 2009.

Risks of Untreated Illness

4. Apter-Levy Y, Feldman M, Vakart A, Ebstein RP, Feldman R:  Impact of maternal depression across the first 6 years of life on the child's mental health, social engagement, and empathy: The moderating role of oxytocin. Am J Psychiatry 2013; 170(10):1161-1168.
5. Center on the Developing Child at Harvard University:  Working Paper #8: Maternal Depression Can Undermine the Development of Young Children. Cambridge, MA, 2009.
6. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al:  The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013; 74(4):e321-e341.
7. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ:  A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010; 67(10):1012-1024.
8. Pearson RM, Evans J, Kounali D, et al:  Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry 2013; 70(12):1312-1319.

Risk/Benefit Analysis and Recommendations

9. Koren G, Nordeng H:  Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol 2012; 207(3):157-163.
10. Yonkers KA, Wisner KL, Stewart DE, et al:  The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31(5):403-413.

Antidepressants in Pregnancy and Breastfeeding

11. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al:  Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014; 348:f6932.
12. Huybrechts KF, Palmsten K, Avorn J, et al:  Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014; 370(25):2397-2407.
13. Hviid A, Melbye M, Pasternak B:  Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med 2013; 369(25):2406-2415.
14. Margulis AV, Abou-Ali A, Strazzeri MM, et al:  Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf 2013; 22(9):942-951.
15. El Marroun H, Jaddoe VW, Hudziak JJ, et al:  Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; 69(7):706-714.
16. Moses-Kolko EL, Bogen D, Perel J, et al:  Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293(19):2372-2383.
17. Sørensen MJ, Grønborg TK, Christensen J, et al:  Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 2013; 5:449-459.
18. Stephansson O, Kieler H, Haglund B, et al:  Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309(1):48-54.
19. Weissman AM, Levy BT, Hartz AJ, et al:  Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants.  Am J Psychiatry 2004; 161(6):1066-1078.
20. O'Connor E, Senger CA, Henninger ML, Coppola E, Gaynes BN: Interventions to prevent perinatal depression: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019; 321(6):588-601.

Bipolar Disorder

20. Burt VK, Bernstein C, Rosenstein WS, Altshuler LL:  Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167(8):892-897.
21. Diav-Citrin O, Shechtman S, Tahover E, et al:  Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 2014; 171(7):785-794.

Psychosis and Antipsychotics

22. Galbally M, Snellen M, Power J:  Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects.  Ther Adv Drug Saf 2014; 5(2):100-109. 
23. McCauley-Elsom K, Gurvich C, Elsom SJ, Kulkarni J:  Antipsychotics in pregnancy. J Psychiatr Ment Health Nurs 2010; 17(2):97-104.
24. Spinelli MG:  Postpartum psychosis: detection of risk and management. Am J Psychiatry 2009; 166(4):405-408.

Substance Use

26. Wong S, Ordean A, Kahan M, et al:  Substance use in pregnancy: SCOG Clinical Practice Guideline. J Obstet Gynaecol Can 2011; 33(4):367-384.

Collaborative Care for Perinatal Women

27. Melville JL, Reed SD, Russo J, et al:  Improving care for depression in obstetrics and gynecology: a randomized controlled trial. Obstet Gynecol 2014; 123(6):1237-1246.